Our understanding of erectile physiology and the pathophysiology of erectile dysfunction (ED) has advanced substantially in recent years, with the determination of the mechanisms involved at both the cellular and molecular levels. Basic research has also unravelled the complex microscopic anatomy of the penis and elucidated how messages are relayed between cells to induce erection. This wealth of information has had major consequences for many millions of men with impotence, or more correctly ED, as it is known today. Clinicians have come to understand that ED is a complex phenomenon and that the patient's problem may be due not only to organic elements but also to psychological causes. Added to this knowledge is a vast array of treatment options that are available to the patient. Over the last decade there has been a considerable shift from the management of ED by the urological surgeon, to the specialist using pharmacotherapy, and more recently to the primary care physician. We have even progressed to the point where patients' expectations, rightly or wrongly, are that a pill can potentially be used as a 'cure' for ED.
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Although the availability of oral agents for the treatment of ED has changed the lives of millions of couples, there is still considerable scope for improvement. The desire for a more holistic approach to management of the ED patient rather than just his erectile function is being increasingly driven by patient demand. Certainly, there is a greater awareness in the medical community of the need for individualisation, to address specifically patients' requirements and expectations particularly of spontaneity and the 'naturalness' of erections.
Established therapies are based on peripheral and direct means of vasodilating the penile vasculature. Apomorphine SL, on the other hand, affects the erection process via the central nervous system (CNS). The CNS is fundamentally involved in the maintenance of normal erectile and sexual function because it initiates signalling to the penis and integrates the overall response. Incorporating our knowledge of CNS control mechanisms, apomorphine SL was developed specifically to improve erectile function in patients with ED. Apomorphine SL is placed under the tongue and selectively activates the dopamine receptors that control erection. The signal then travels down the sympathetic and parasympathetic pathways to nerves in the pelvic area, dilating the cavernosal vasculature and causing an erection.
Over 5000 patients have taken part in clinical trials and apomorphine SL has also been evaluated across a broad spectrum of ED patients with diverse aetiologies, severities of ED (including severe) and co-morbidities. The studies have included men with coronary artery disease, diabetes mellitus, dyslipidemia and hypertension, as well as men on medication including antihypertensive drugs and nitrates. Nearly half of the patients in the apomorphine SL clinical database had severe ED at baseline, as determined by the erectile function domain of the International Index of Erectile Function (IIEF). Thus this database may be representative of a more severe population than that which routinely presents in the physician's office.
Endpoints were chosen to represent definable measurements of qualitative and quantitative improvements in ED and patient quality of life. These endpoints include patient and partner evaluation of the suitability of the erection for intercourse and actual intercourse rates achieved, assessed at each attempt. Irrespective of the endpoint analysis, there were highly significant improvements over both baseline and placebo. Efficacy was similar in all clinically important ED subpopulations and the response to apomorphine SL was durable. In patients responding to apomorphine SL, over 90% of attempts produced erections firm enough for intercourse in long-term studies. Additionally, apomorphine SL provided rapid onset of the erectile response in ED patients, with the majority of erections occurring within 20 min.
At the approved doses (2 and 3 mg) the most common side effect was mild to moderate nausea that tended to disappear on repeat dosing. Patients typically described the sensation as being equivalent to butterflies at exam time. No deaths, myocardial infarctions or cerebrovascular accidents have been attributed to apomorphine SL.
Overall, the data show that apomorphine SL is effective and safe across the broad aetiological causes and severities of ED in the patients that are likely to present to specialists and primary care physicians. The profile of a significant improvement of erectile function, spontaneity, consistency and excellent tolerability would appear to meet the goal for use as front line therapy for the management of ED patients.
The articles covered in this supplement are designed to provide firstly a detailed scientific description of the role of dopamine in the control of normal erectile function and in the pathophysiology of ED. In addition, the rationale for the development of apomorphine SL and its clinical profile are reviewed. The clinical data is presented in relation not only to primary efficacy and safety but also in the context of how apomorphine SL is likely to be used in the management of the ED patient in the 'real world' setting of the physicians' office and the patient's daily life.
In conclusion, I believe that the advent of apomorphine SL will make a welcome addition to the therapeutic armamentarium of every physician dealing with patients with ED. Of equal importance will be the potential advantages that this novel therapy will have in terms of meeting patients' expectations.
